Altamira Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

HAMILTON, BERMUDA, Dec. 29, 2023 (GLOBE NEWSWIRE) -- HAMILTON, BERMUDA, Dec. 29, 2023 -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company providing nanoparticle-based technology for efficient RNA delivery to extrahepatic targets, announced that it received a notification letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq") on December 28, 2023, indicating that the Company has regained compliance with the minimum bid price requirement. As a result, the listing matter has been closed.

See the original post:
Altamira Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Related Posts